Fortrea (FTRE) Expected to Announce Earnings on Thursday

Fortrea (NASDAQ:FTRE) is projected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Fortrea to post earnings of $0.16 per share and revenue of $665.2220 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:00 AM ET.

Fortrea Stock Up 7.6%

Shares of FTRE stock opened at $10.44 on Thursday. The stock’s 50-day simple moving average is $15.91 and its 200-day simple moving average is $12.15. The firm has a market capitalization of $964.66 million, a PE ratio of -0.93, a P/E/G ratio of 0.28 and a beta of 1.59. Fortrea has a fifty-two week low of $3.97 and a fifty-two week high of $18.67. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.00 and a current ratio of 1.00.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on FTRE shares. Wall Street Zen cut shares of Fortrea from a “buy” rating to a “hold” rating in a research note on Monday, October 27th. Barclays set a $15.00 target price on Fortrea and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Truist Financial set a $22.00 price objective on shares of Fortrea and gave the stock a “buy” rating in a research report on Thursday, January 8th. Citigroup raised shares of Fortrea from a “neutral” rating to a “buy” rating and raised their price objective for the company from $12.00 to $21.00 in a research note on Thursday, December 11th. Finally, Mizuho set a $15.00 price objective on Fortrea in a research report on Friday, January 9th. Four research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Fortrea has a consensus rating of “Hold” and a consensus price target of $16.75.

Institutional Trading of Fortrea

Several hedge funds have recently modified their holdings of the business. AQR Capital Management LLC increased its holdings in shares of Fortrea by 494.8% in the 2nd quarter. AQR Capital Management LLC now owns 6,515,124 shares of the company’s stock valued at $31,729,000 after purchasing an additional 5,419,842 shares in the last quarter. State Street Corp boosted its position in Fortrea by 1.0% during the fourth quarter. State Street Corp now owns 4,110,899 shares of the company’s stock worth $70,913,000 after acquiring an additional 39,777 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Fortrea by 21.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,219,029 shares of the company’s stock worth $55,528,000 after buying an additional 565,891 shares during the period. Deutsche Bank AG increased its position in Fortrea by 0.3% during the fourth quarter. Deutsche Bank AG now owns 2,556,193 shares of the company’s stock worth $44,094,000 after purchasing an additional 7,685 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Fortrea by 9.4% in the fourth quarter. Geode Capital Management LLC now owns 2,278,934 shares of the company’s stock valued at $39,318,000 after acquiring an additional 196,759 shares during the last quarter.

About Fortrea

Fortrea, Inc is a global contract development and manufacturing organization (CDMO) that provides integrated solutions for pharmaceutical and biotechnology companies. Established as a spin-off from Thermo Fisher Scientific’s Pharma Services business in October 2023, Fortrea leverages a legacy of scientific expertise and manufacturing scale to support drug development from early-stage research through commercial production. The company’s comprehensive offerings address the complex needs of both small-molecule and biologics programs, making it a single source for clients seeking to accelerate timelines and manage costs.

Fortrea’s core services encompass analytical and formulation development, process optimization, clinical and commercial manufacturing, and packaging services.